Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

OSLO, Norway, Aug. 27, 2025 /PRNewswire/ -- Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing recruitment.

Highlights for the first half of 2025:

Radspherin®

Positive final data from Phase1/2a trial in colorectal cancer patients

Positive interim 18-months data from Phase1 trial in ovarian cancer patients

Positive read-out of safety lead-in cohort and opening of randomized part of Phase 2 trial in ovarian cancer patients

Regulatory approvals for additional sites for the randomized Phase 2 trial in ovarian cancer, with expected onboarding before end of 2025

Corporate

Operating expenses reduced by 28% versus last year

Merger with BerGenBio

Fully guaranteed rights issue of NOKm 130

CEO Øystein Soug and CFO Tore Kvam will present the results for the first half of 2025 at a webcast available at https://channel.royalcast.com/landingpage/hegnarmedia/20250827_3/, Wednesday 27 August at 08:00 CEST. The presentation and Q&A will be held in English. A recording of the webcast will be made available on our website shortly after the presentation.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead ...